Extracellular Vesicles as Drug Delivery Vehicles for Cancer Therapy
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Biologics and Biosimilars".
Deadline for manuscript submissions: 31 May 2024 | Viewed by 410
Special Issue Editors
2 Department of Surgery, Immunology Program, Cancer Program and Nanomedicine Translational Program, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117600, Singapore
3 Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR), Singapore
Interests: extracellular vesicles; cancer immunology; cell biology
Special Issue Information
Dear Colleagues,
Extracellular vesicles (EVs) are lipid bilayer particles that function as carriers of intercellular communication under both physiological and pathological conditions. Not surprisingly, EVs have gained popularity as efficient vehicles, delivering therapeutic cargoes for cancer therapy. Nevertheless, efforts toward the standardization of methods of purification and production, drug loading and encapsulation, and surface functionalization for improved circulation kinetics and enhanced target specificity have yet to achieve the therapeutic potential of EVs for clinical use. Currently, EV microencapsulation with nanoporous biomaterials represents a great challenge in the field of controlled drug delivery. While the overwhelming majority of EV-based therapies in clinical trials consist of naïve EVs, contemporary progress in EV engineering is contributing to the development of more sophisticated drug delivery systems.
In this Special Issue, we invite the submission of review or original articles on all aspects related to EVs, including therapeutic applications of EVs for cancers, the loading of EVs with therapeutic cargoes, new approaches in targeted drug delivery, and regulatory considerations with regard to scale-up production, purity, safety, stability, and biocompatibility.
Dr. Thi Nguyet Minh Le
Dr. Boya Peng
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- drug delivery system
- targeted delivery
- microencapsulation
- circulation kinetics
- anticancer therapy
- manufacturing process
- clinical translation
